Aopeng Yiliao
Series C in 2025
Aopeng Yiliao is a developer of vascular interventional surgery robots.
Zhitong Technology
Series A in 2024
Zhitong Medical is a provider of computational imaging technology that focuses on the development of surgical vision.
Medtech Technology
Series B in 2024
Medtech Technology is a firm that develops innovative ophthalmic medical devices.It has developed its own artificial lens production and research technology platform, as well as a technological barrier to high-end artificial lens manufacture.
GenomePrecision
Series C in 2024
Beijing GenomePrecision Technology Co., Ltd. is a molecular diagnostic company focused on developing precision medicine tests to enhance the diagnosis and treatment of various diseases, including blood tumors, transplantation needs, and cardiovascular conditions. Established in 2015 and headquartered in Beijing, the company integrates research and development, manufacturing, distribution, and registration of its products. GenomePrecision utilizes advanced molecular technology platforms, such as real-time fluorescence quantitative PCR, Sanger sequencing, high-throughput next-generation sequencing, and capillary electrophoresis, to create a diverse range of diagnostic products. These include tests for leukemia, lymphoma, solid tumors, and pharmacogenomics, as well as tools for organ transplant monitoring and pathogen detection. The company also produces molecular diagnostic kits for targeted drug testing and auxiliary diagnosis of cervical cancer, among other applications. By focusing on clinical diagnosis and treatment requirements, GenomePrecision aims to improve patient outcomes through innovative molecular diagnostics.
Better MedTech
Seed Round in 2024
Better MedTech is a company dedicated to advancing urinary and pelvic floor health through the research, development, and production of specialized medical devices. It focuses on creating innovative solutions for conditions such as benign prostatic hyperplasia, urinary incontinence, urinary stones, and novel tumor therapies. By combining cutting-edge technology with comprehensive medical expertise, Better MedTech aims to deliver precise and effective products that enhance patient care and improve outcomes in these critical areas of health.
JH Cispoly
Series B in 2023
JH Cispoly specializes in the development of diagnostic technology and equipment specifically aimed at the early detection of gynecological tumors. The company focuses on innovative solutions for identifying ovarian, cervical, and endometrial cancers, among others. By enhancing the capabilities for early diagnosis, JH Cispoly plays a crucial role in improving patient outcomes through timely intervention in gynecological health.
Juhe Biotechnology
Series B in 2023
Juhe Biotechnology is a company that creates early detection tools for gynecological malignancies.
Precedo Biomedical
Series B in 2023
Precedo Biomedical is a high-tech business that specializes in industrial safety & national strategic biosafety through core cell engineering technologies. It employs the innovation-driven development approach, which leverages scientific and technological innovation to propel industrial innovation, to conduct industrialization and scientific research centered on "cell" issues that impede biomedical development.
Jiyuan Medical
Series A in 2023
Jiyuan Medical specializes in the development and distribution of disposable gynecological endoscopes and related products. Their portfolio includes a range of disposable electronic hysteroscopes, such as 4K high-definition mirrors, resectoscopes, and near-infrared mirrors, along with disposable gynecological surgical instruments and intelligent workstations. The company aims to provide comprehensive solutions for disposable gynecological endoscopy, focusing on efficiency and patient care.
BD Gene Therapeutics
Series B in 2023
BD Gene Therapeutics is a biotechnology company focused on developing gene therapy drugs to address genetic diseases, particularly eye conditions. The company employs a gene-editing platform that utilizes mRNA delivery technology and fourth-generation lentiviral vectors, facilitating the safe and efficient delivery of gene-editing tools like CRISPR. BD Gene Therapeutics is dedicated to discovering innovative treatments for conditions such as diabetic macular degeneration, age-related macular degeneration, and herpes simplex keratitis. In addition to its gene therapy initiatives, the company has also developed antiviral eyedrops and explores applications in tumor immunity and regenerative medicine.
Human Zhizao
Series A in 2023
Human Zhizao is a technology platform that provides comprehensive diagnostic solutions. They provide clinical customers with a parallel, full-automatic multiple flow cytometry fluorescence detection platform and supporting reagents. They provide customer service. The flow fluorescence luminescence technology is a new generation of throughput detection and analysis platform integrating flow analysis, laser analysis, digital signal processing, and other technologies. They involve projects that require the joint detection of multiple indicators, such as autoantibodies, allergens, cytokines, etc.
Hexin Pharmaceutical
Series A in 2023
Hexin Pharmaceutical is a developer of nuclide drugs integrating targeted diagnosis and treatment.
Forethought
Seed Round in 2023
Forethought is engaged in the research and development, production, sales, and service of intelligent and medical devices. They provide products for their classmate xiaoshu spinal detector, spine data acquisition, and analysis system. They offer solutions for hospital testing, student medical examinations, rehabilitation, Fitness Sports Dance Agency, and home guardianship.
Huamu Medical
Series C in 2023
Huamu Medical is a medical device company that uses global innovative technologies to treat cervical spine diseases. It mainly develops and produces new self-locking and absorbable cervical spine cage products. The company's team brings together top domestic material experts and medical experts, and is committed to bringing products to domestic and foreign markets, benefiting the majority of patients with genuine Chinese innovative technologies and products.
Farmove Medical
Series C in 2023
Farmove Medical is a company focused on the development and technical consultation of medical device technologies, particularly for the monitoring and early detection of chronic diseases affecting the cardiac, nervous, endocrine systems, and hypertension. Additionally, the company specializes in the research and development of innovative solutions for spinal diseases, including self-locking and absorbable cervical fusion cage technologies designed for cervical spine treatment. By providing essential medical equipment and expertise, Farmove Medical aims to enhance healthcare outcomes in the management of chronic and spinal conditions.
MEIHUAMEDICAL
Series B in 2022
MEIHUAMEDICAL develops, produces and sells microbial medical instruments & diagnostic reagents.
Prime Gene Therapeutics
Series A in 2022
Prime Gene Therapeutics is committed to becoming a pharmaceutical company. They focus on new drug discovery, R&D, and commercialization in inflammatory diseases and external use. They are also developing and industrialization of innovative drugs.
IMADEK specializes in the research, production, and sale of innovative in vitro diagnostic (IVD) products and medical equipment. The company develops a range of solutions, including automatic sampling systems, sample processing systems, and intelligent blood storage platforms. Its offerings also include automatic nucleic acid extractors and liquid handling modules, catering to various sectors such as molecular diagnostics, blood screening, enzyme immunoassay, and mass spectrometry. Additionally, IMADEK focuses on enhancing blood management through intelligent systems, such as cold chain temperature monitors and epidemic control information management systems, aimed at improving blood supply, testing, and storage.
NeuroEchos
Series A in 2022
NeuroEchos, established in 2017, specializes in functional neurosurgery with a focus on precise electroencephalogram (EEG) technology. The company offers integrated diagnostic and treatment solutions for diseases resulting from abnormal nervous system discharges. NeuroEchos utilizes artificial intelligence-assisted decision-making software to accurately interpret EEG waves, enhancing the diagnosis process. Additionally, they contribute to neuroscience research through their advanced deep brain electrodes.
EnnovaBio
Series B in 2021
EnnovaBio is a Chinese biopharmaceutical company that specializes in the development of innovative drugs targeting brain glioma and prevalent autoimmune diseases. The company focuses on creating targeted therapeutic drugs aimed at treating various autoimmune and inflammatory conditions, utilizing advanced immunotherapy techniques. By prioritizing research and development, EnnovaBio aims to provide sophisticated and effective treatment options for patients and healthcare professionals in China.
Leo Medical Co.
Venture Round in 2021
Leo Medical is a high-tech medical company that creates, produces, and sells cutting-edge medical products. Leo Medical develops medical devices that use cutting-edge biomedical technology to aid in the diagnosis, intervention, and treatment of disorders of the digestive and circulatory systems. They feel that a minimally invasive technique is the most humane way to treat patients while without sacrificing the procedure's quality. Minimal invasion in medical treatments frequently allows patients to heal faster and doctors to simplify medical operations. It is a win-win situation for everyone. Leo Medical was founded in 2011 and is headquartered in Jiangsu, P.R. China.
JH Cispoly
Seed Round in 2021
JH Cispoly specializes in the development of diagnostic technology and equipment specifically aimed at the early detection of gynecological tumors. The company focuses on innovative solutions for identifying ovarian, cervical, and endometrial cancers, among others. By enhancing the capabilities for early diagnosis, JH Cispoly plays a crucial role in improving patient outcomes through timely intervention in gynecological health.
Qianglian Zhichuang
Series B in 2020
the first high-tech company in China to focus on the treatment of cerebrovascular disease, it has more than four years of product research and development, leading China's cerebrovascular disease intelligence in an all-around way. vertical field of diagnosis and treatment. It has become a well-known brain stroke intelligence diagnosis and treatment platform in China.
Suzhou Bonsmile Medical Technology
Series B in 2020
Suzhou Bonsmile Medical Technology Co., Ltd. specializes in manufacturing stealth orthodontics products, focusing on invisible orthodontic appliances that do not require brackets. Founded in 2016 and located in Suzhou, China, the company offers advanced technologies such as SSP root control technology, SSP3D design software, and cone beam computed tomography (CBCT) imaging. These innovations enable the correction of dental deformities and the customized production of clear aligners, providing both patients and dental professionals with effective and safe orthodontic solutions.
PandaMed
Seed Round in 2019
PandaMed, officially known as Changzhou Zhishan Medical Technology Co., Ltd., is a high-tech company established in May 2017, dedicated to the research, development, and industrialization of non-invasive medical devices focused on diabetes and weight loss. Headquartered in the West Taihu Hi-Tech Industrial Park in Changzhou, the company was founded by a team of domestic and international medical experts and experienced practitioners in the medical equipment field. PandaMed specializes in developing solutions for obese patients, offering services that include an intragastric balloon system and comprehensive health management. The company also has a research and development center located in Shanghai, further enhancing its capacity for innovation in chronic disease treatment and non-invasive weight loss solutions.
Beijing DeepWise Science And Technology Co., Ltd. is a company that specializes in developing artificial intelligence-based medical application software aimed at enhancing clinical imaging analysis and diagnostics. Founded in 2017 and located in Beijing, China, DeepWise focuses on early screening and diagnosis of various malignant diseases, including lung and breast cancers. Its AI-driven software improves efficiency and diagnostic accuracy in healthcare, offering solutions to hospitals, medical centers, and imaging centers. The company's technology supports the online reading and consultation of medical images, leveraging big data in the cloud to facilitate timely and accurate disease detection and treatment.
UPPER
Venture Round in 2019
UPPER is a biomedicine manufacturing firm. They provide a maya fluoresence analyzer, an ottoman automatic protein analyzer, and other products. Upper Biotech Pharma markets its products.
Ligatech Bioscience
Series A in 2017
Ligatech Bioscience, established in 2014 and headquartered in Qingpu, China, specializes in the design, development, production, and sales of medical devices for orthopedic and sports medicine. Its product portfolio includes molecular weight polyethylene suture and striped titanium plates, along with artificial ligaments and fixation systems. The company also offers technical advice and services to its users.
Regenex Corporation
Angel Round in 2016
Regenex Corporation Co. Ltd. is a pharmaceutical company based in Guangzhou, China, founded in 2003. It specializes in the research, development, and manufacturing of a diverse range of pharmaceutical products. The company's product portfolio includes reproductive health medicines, such as oral contraceptives and emergency contraceptives, as well as condoms with water-based lubricants. In addition, Regenex produces anti-neoplastic drugs, including liposomal formulations for cancer treatment, and antibiotic agents like Amphotericin B for injection. The company also focuses on developing medications for chronic diseases and geriatric care. Through its innovative approaches, Regenex strives to enhance healthcare outcomes while managing its marketing operations effectively.
MicroClear Medical
Series A in 2015
MicroClear Medical specializes in the development and manufacturing of medical instruments aimed at enhancing ophthalmology and optometry imaging services. The company offers a range of high-quality optical equipment, including a confocal retinal ophthalmoscope, a handheld fundus camera, a handheld slit lamp, and a vision screener. Utilizing artificial intelligence technology, MicroClear's products are designed to facilitate improved diagnostic accuracy for healthcare professionals. The company serves hospitals and basic medical institutes worldwide, providing accessible and advanced imaging solutions to support eye care.
Genesky Technology (Suzhou) Co., Ltd. is a private company based in China, established in 2008, that specializes in the development and application of gene analysis technology. The company focuses on enhancing medical diagnostic accuracy through its genetic analysis services. It develops molecular diagnostic reagents and medical tests aimed at disease examination and provides hospitals with genetic testing services. By doing so, Genesky enables healthcare providers to improve diagnostic precision and make informed decisions regarding disease treatment.
Pharmplus
Series B in 2015
Pharmplus is dedicated to building a contemporary chain pharmacy that blends products and services from online and offline sources. For stores, it offers pharmaceutical services. Their goal is to become a professional steward of hundreds of millions of people's health.